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Functional Attributes and Health 
Benefits of Novel Prebiotic 
Oligosaccharides Derived from 
Xylan, Arabinan, and Mannan
Bradley A. Saville and Sandra H. Saville
Abstract
Prebiotic oligosaccharides are produced from many different sources, with sub-
stantial differences in chemical structure, bonds between subunits, and degree of 
polymerization. These structural differences can materially affect microbial utiliza-
tion and the dose required for efficacy. Most prebiotic oligosaccharides are based on 
subunits comprised of 6-carbon sugars such as glucose/fructose and alpha bonds. 
Newer/novel oligosaccharides are derived from 5 carbon sugars and/or connected 
via beta bonds. Clinical trials with xylooligosaccharides, arabinoxylanoligosaccha-
rides, and mannooligosaccharides have shown improvements in lipids, cholesterol, 
management of blood glucose, weight management, and laxation, at doses typically 
ranging from 1 to 4 g per day. Mannooligosaccharides are also showing promise for 
animal health, with the potential to reduce antibiotic use. These novel prebiotics are 
showing promise due to greater selectivity and their ability to deliver health benefits 
at a lower dose compared to conventional prebiotics.
Keywords: xylooligosaccharide, mannooligosaccharide, arabinoxylooligosaccharide, 
prebiotics, human health, clinical trials, animal studies
1. Introduction
There is increasing recognition of the beneficial role of prebiotics in modulating the 
microbiome of humans and animals, with the opportunity to beneficially impact health. 
While the initial focus has been the digestive tract, there has been increasing attention 
on modification of the microbiome on the skin, in the mouth, and in the urogenital tract. 
The efficacy of prebiotics is predicated upon selectively feeding beneficial microbes 
within the target region, with key metabolites, inflammatory and immune markers, etc. 
driving “distal” health benefits. Within this chapter, we focus on prebiotics that modulate 
the microbial community in the digestive tract, with a specific focus on novel prebiotics 
that are based upon 5-carbon sugars as well as 6-carbon sugars with less common beta 
bonds. When prebiotics are consumed, they are feeding a mixed community of microbes 
in a dynamic environment in the gastrointestinal tract, where carbohydrates (polymers, 
oligomers, dimers, monomers) of various types are broken down by digestive enzymes, 
absorbed into the bloodstream, and utilized by microbes via specific transport and 
enzyme systems. We elaborate on these concepts in sections 2 and 3, below.
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We thus start by describing the environment within the digestive tract – diges-
tive enzymes, systems for carbohydrate absorption, and the microbial communities 
therein. We then discuss various types of prebiotics, with a particular emphasis 
on differences in subunits and bond structure. These differences, coupled with 
differences in microbial enzymes and transport systems, contribute to differences 
in efficacy, selectivity, and dose between prebiotics. We then focus on prebiotics 
derived from xylan, arabinan, and mannan, differentiating them from “conven-
tional” prebiotics that rely on subunits of common 6-carbon sugars. Finally, we 
discuss results from clinical and animal trials with these novel prebiotics, discussing 
impacts on human and animal health.
2.  The gastrointestinal tract, gut microbiota, and carbohydrate 
absorption
Downstream of the stomach, the digestive tract is comprised of the small intes-
tine and the colon. The colon is often discussed in terms of the proximal and distal 
regions, which is relevant in the context of prebiotics, considering both rates and 
locations for bacterial growth. The small intestine is the primary region for drug 
and nutrient absorption, although some nutrients and metabolites from microbial 
growth and metabolism are also absorbed from the colon, where the majority of 
the gastrointestinal bacteria reside. The transit time through the small intestine is 
very short – only a few hours, whereas the transit time through the colon may be on 
the order of 30–40 hours or more, depending upon dietary fiber and fluid intake, 
among other factors [1].
2.1 Enzymes and nutrient absorption in the digestive tract
The small intestine of the human gastrointestinal system contains amylases 
(from the pancreas) to break down glycogen and starch, a 6-carbon sugar with 
α-1,4 bonds, and brush border enzymes (lactase, maltase, dextrinase, sucrase) to 
break down short chain glucooligosaccharides and disaccharides such as sucrose, 
lactose, and maltose into glucose, fructose, and galactose [2]. Other enzymes aid 
in the digestion of fats and proteins. The epithelium in the jejunum and ileum of 
the small intestine is also specifically designed to absorb 6-carbon sugars such as 
glucose, fructose and galactose via passive, facilitated and active transport systems. 
Dimers must be broken down into monomers before absorption, and oligomers 
can persist further into the colon, where they feed microbes that contain enzymes 
and transport systems to break down complex polymers and oligomers such as 
xylan and inulin. Short chain fatty acids (SCFAs) can be absorbed from the small 
intestine, or from the colon if produced as metabolites of bacterial fermentation. 
It is estimated that >90% of the SCFAs produced in the colon are absorbed, where 
they can influence, e.g., hepatic regulation of glucose and lipids, and hormones that 
regulate satiety [3].
2.2 Microbial communities in the digestive tract
The digestive tract is proposed to contain about 1013 bacteria, with 100–300 
different taxa and thousands of phenotypes [4]. The dominant gut bacteria 
identified by 16S RNA are Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, 
Verrucomicrobia. The small intestine, where simple carbohydrates are abun-
dant, contains about 1–10000 bacteria per gram of intestinal content, primarily 
Clostridium, Bacteroides, and Streptococcus species. Zoetendal et al. [5] sampled 
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the small intestine of four healthy subjects, and observed that Bacteroidetes, 
Clostridium (clusters XIVa, IV, XI, and IX) and Proteobacteria dominated, with 
some Actinobacteria and Bacilli also present. Zoetendal et al. [5] provides evidence 
that the microbiota, particularly Streptococcus species, in the small intestine adapts 
rapidly to changes in dietary intake, particularly carbohydrates, based upon the 
presence of transport systems and enzymes that quickly and efficiently utilize 
simple carbohydrates.
The colon, which survives on complex carbohydrates that are not digested or 
absorbed in the small intestine, contains about 1011 bacteria per gram of intestinal 
content, mainly Prevotella, Ruminococcus, and Bacteroides. Mucin degraders such as 
Akkermansia mucinophila are commonly found in the mucous layer. The GI tract, 
for various reasons, may also contain pathogenic bacteria at levels that may or may 
not be clinically significant. Furthermore, there is increasing recognition of the 
impact of the gut microbiota on the efficacy of drugs, since some microbes contain 
enzymes similar to those in the liver [6, 7], or may initiate breakdown of prodrugs. 
Such effects have been observed with metformin and L-DOPA, among other drugs, 
and may account for at least part of the interindividual variation in drug efficacy 
and side effects.
Most microbes evolved to process conventional 6 carbon sugars, particularly 
monomeric glucose, fructose and galactose. A smaller fraction is able to use man-
nose, arabinose, and xylose [8].
3. Background on prebiotics
3.1  Definition, brief description of different types of prebiotics, their structure, 
and function
Historically, the definition of prebiotics was specific to oligosaccharides 
affecting the gut microbiome, and health impacts arising therein. Recently, the 
International Scientific Association for Probiotics and Prebiotics modified the con-
sensus definition to include other types of compounds that may act as prebiotics, 
and also included prebiotics that could work outside of the digestive tract [9]. Even 
so, it is essential that that a prebiotic must selectively stimulate the growth of benefi-
cial bacteria, and that there must be a health benefit arising from the consumption/
application of the prebiotic. Molecules such as antibiotics that modify the micro-
biome by acting as antimicrobial agents against undesirable bacteria would not be 
considered prebiotics, since they do not act as substrates for beneficial bacteria.
Fructans such as inulin and fructooligosaccharides (FOS) are most common 
among prebiotics in the marketplace, although galactooligosaccharides (GOS) 
produced from lactose are also available, and xylooligosaccharides (XOS) were 
available in Japan since the 1980s [10]. Recently, forms of resistant starch (RS), 
isomaltooligosaccharides (IMOS), arabinoxylooligosaccharides (AXOS) and man-
nooligosaccharides (MOS) have become available commercially.
Fundamentally, these prebiotics are all materially different, even though the end 
goal – promoting growth of beneficial bacteria, is the same. The types of bacteria 
that can be fed by each of these prebiotics depend upon enzymes and transport 
systems present in the bacteria, which can vary considerably. The selectivity of a 
prebiotic is also tied to these enzyme and transport systems; if a high percentage of 
the bacteria have the necessary enzymes and transport systems, then the prebiotic 
will feed a diverse array of bacteria, including beneficial bacteria along with unde-
sirable bacteria. Conversely, a highly selective prebiotic may not feed many types 
of bacteria, because fewer types of microbes have the right microbial “machinery” 
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to utilize these prebiotics. Such prebiotics are less likely to directly feed undesirable 
bacteria if these bacteria do not have the right transport systems and enzymes. 
Below, we describe the different chemical structures of prebiotics, along with the 
enzymes and transport systems responsible for their utilization.
3.2 Chemical structures of prebiotics
Prebiotics are typically comprised of oligomers of 6-carbon and/or 5-carbon 
sugars, with different bonding structures, and different chain lengths (see Figure 1 
for examples) [11].
Fructans from inulin are typically linear oligomers primarily made up of fruc-
tose monomers connected by β-2,1 bonds. Fructans from agave tend to have a more 
complex structure with multiple side branches and β-2,6 linkages in addition to 
β-2,1 bonds [12]. FFn-type fructans such as inulin are comprised entirely of fructose 
subunits, whereas GFn-type fructans (typically shorter chain oligosaccharides) may 
have a glucose subunit connected by an α-2,1 bond onto the main fructan chain. 
These short-chain GFn-type FOS molecules are typically produced by enzymati-
cally adding fructose subunits onto sucrose (glucose-fructose) as the starting 
substrate. In contrast, short chain FFn FOS would be produced by hydrolysis of 
inulin (long chain FFn) using endoinulinases [11, 12].
Galactooligosaccharides (GOS) may also be comprised exclusively of galactose 
subunits, or it may have a glucose terminal subunit arising from use of lactose 
(glucose-galactose) as the initial substrate to produce GOS using β-galactosidases. 
The galactose subunits may be connected by β-1,3, β-1,4, or β-1,6 bonds, and may 
include branched structures, depending upon the type of β-galactosidase [11, 13].
Xylooligosaccharides (XOS) are primarily comprised of xylose subunits 
connected by β-1,4 bonds, although longer chain XOS may contain branches of 
arabinose subunits, acetyl groups, or uronic acids (originally present in the xylan 
source material) that can influence their functionality. XOS that includes arabi-
nose sub-groups are frequently referred to as arabinoxylanoligosaccharides, or 
AXOS [11, 14].
Mannooligosaccharides are derived from mannan in biomass, and thus 
are typically made up of mannose subunits connected by β-1,4 bonds [15]. 
Isomaltooligosaccharides (IMOS) contain glucose subunits, but vary in their bond-
ing structure (affected by manufacturing method). α-1,6 bonds are typical, with 
either linear or branched structures [11].
Complex starch structures that resist breakdown by pancreatic enzymes into 
glucose can persist into the colon – thus leading to the concept of “resistant starch” 
as a prebiotic. Resistant starch (RS) is available in four forms, depending upon 
method of manufacture and bond structure [16, 17]. Like starch, most of the bonds 
are of the α-1,4 variety; the presence of other types of bonds may confer “resis-
tance”. RS1 is conventional starch that may be trapped within whole grains. RS2 
is typically starch with more complex branching or bond structures, rendering it 
less accessible to amylase. RS3 is produced when starch undergoes retrogradation, 
i.e., cooked starch is cooled below its gelatinization temperature. RS4 starches have 
undergone chemical modification, usually by acidification or cross-linking [16].
The microbial ability to utilize specific substrates is dependent upon the 
enzymes and transporters encoded within the cells. Some microbes can utilize 
a broad set of substrates, while others are more selective. This also points to the 
selectivity of the prebiotic; preferably, the prebiotic preferentially feeds beneficial 
bacteria, with limited growth of undesirable bacteria. Table 1 summarizes the 
key hydrolytic enzymes and the corresponding substrates/reactions [19]. These 
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enzymes may be extracellular, or intracellular, which can influence substrate utili-
zation; intracellular enzymes require a corresponding transporter system.
There are various types of transport systems that move prebiotics into the cell, 
although microbes are likely to only possess a subset, targeted towards a narrower 
set of substrates. Some transport systems are specific to (certain) monomers, while 
others target specific oligosaccharides. Chemical structures must be matched to the 
structure of the transport system in order to be transported into the cell. Table 2 
summarizes key membrane transport systems involved in utilization of prebiotics 
and other carbohydrates.
From a selectivity perspective, it is advantageous if the substrate is used intracel-
lularly – thus, the requisite transport system plus intracellular fructofuranosidases 
Figure 1. 
Chemical and bonding structures of prebiotics.
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would have an advantage (i.e., FOS that can be transported intracellularly would 
have an advantage over FOS/inulin that can only be processed via extracellular 
enzymes). The restricted capacity of most transporter systems precludes use of long 
chain fructans by many Lactobacillus species [11].
3.3 Types of microbes with enzyme/transport systems of various types
Microbes that have fructofuranosidase encoded extracellularly are able to use 
long-chain FFN-type FOS, and inulin. Some species of Lactobacillus (casei, paraca-
sei) and Streptococcus are examples [11]. The resulting short chain fructans may be 
transported intracellularly for utilization. Mao et al. [23] identified 19 strains from 
human feces that were capable of metabolizing FOS, including multiple strains of 
E. coli, Enterobacter cloacae, Bifidobacterium spp., and Lactobacillus spp. Additional 
bacteria also proved capable of growth on FOS. This includes additional strains 
of E. coli and Bifidobacteria, along with several strains of Streptococcus, Clostridia, 
Roseburia, Klebsiella, and Enterococcus [23].
According to Rossi et al. [24], virtually all Bifidobacteria are able to grow on 
short-chain FOS. However, most Bifidobacteria grew poorly on inulin (only 8 out of 
55), because most of the fructofuranosidases are intracellular, and inulin cannot be 
transported intracellularly. Scott et al. [25] made similar observations when inulin 
with a DP >25 were fed to Bifidobacteria. However, in a mixed culture system, inulin 
may be broken down into shorter chain FFn-FOS, and then used by Bifidobacteria. 
Thus, growth of Bifidobacteria in the presence of inulin is primarily due to cross-
feeding in the presence of other microbes that act as primary degraders, rather than 
direct feeding by inulin.
Different species of Bifidobacteria contain ABC transporters, sucrose perme-
ases, fructose PTS transporters, and MFS transporters. The type(s) of available 
transporters dictate substrate utilization, whether GFn-type short chain FOS, 
FFn-type FOS, or analogous substrates. Although several strains of Bifidobacteria 
can utilize GOS, there are significant differences between strains [26]. Certain 
strains of B. breve and B. longum contain an extracellular galactanase that 
breaks down long-chain GOS and galactan in plant fiber, producing di- and 
Enzyme Substrates, reactions
α-amylase, glucoamylase, 
pullulanase
Converts starch and RS into glucose
Inulinase, β-fructofuranosidase Converts inulin into FOS, and FOS into fructose/glucose
β-galactosidases Converts lactose into glucose and galactose; aids individuals with 
lactose intolerance [18]
β-Endoxylanases, β-xylosidases Converts XOS into short chain XOS (sc-XOS) and xylobiose, then 
xylose
β-endoglucanase, cellobiohydrolase, 
β-glucosidase
Converts cellulose and β-gluco-oligosaccharides into cellobiose, then 
glucose
β-galactanase, β-galactosidase, 
α-galactosidase
Converts galactan into β-GOS, then galactose; β-galactosidase can 
also remove galactose subunits that are present as side chains in 
xylan/XOS
β-mannanase, β-mannosidase Converts MOS into mannobiose, then mannose
α-arabinofuranosidase Releases arabinose from side chains of xylan and AXOS
Table 1. 
Key enzymes for carbohydrate utilization.
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tri-saccharides that can be transported into the cell and converted into galactose 
via intracellular β-galactosidase [27]. B. lactis BI-04 contains lactose permease 
and ABC transport systems, along with β-galactosidase [28], that enable utiliza-
tion of GOS. L. acidophilus has the ability to utilize many different prebiotics, 
with various monomeric subunits and bond structures [28]. Such broad utili-
zation is due to a multiplicity of molecular transport systems and hydrolytic 
enzymes, including up to nine different enzymes from the GH13 family that act 
on α-glucan [11].
Transport system Target molecules Examples/implications
ATP-dependent binding 
cassette (ABC-type) 
transporter system
There are many variations 
of the ABC transporter. 
Transporters in the CUT1 
class work on sucrose, 
lactose, maltose, FOS, 
maltodextrins, XOS, and other 
oligosaccharides. Transporters 
in the CUT2 class generally 
transport monomers such 
as arabinose, xylose, ribose, 
glucose [20, 21]
Such a system is present in L. 
acidophilus, for utilization of 
short-chain FOS; Bifidobacteria have 
an ABC transporter specific to XOS; 
various enterobacteria, including 
E. coli, have CUT1 and CUT2 
transporters for maltose and various 
6-carbon sugars
Sucrose phosphoenolpyruvate 
phosphotransferase (PTS) 
transport system
Transport system is highly 
specific to compounds that 
incorporate sucrose as part of 
their structure.
Allows L. plantarum to utilize short-
chain FOS synthesized from sucrose 
(GFn-type), but FFn FOS, which 
lacks the sucrose structure, cannot 
be used by L. plantarum
Major facilitator superfamily 
(MFS) transporter system
A major transporter system 
with various types, allowing 
intracellular transport of 
glucose, lactose, xylose, 
oligosaccharides, FFn-type FOS 
[11, 21]
Present in many bacteria, fungi, 
yeasts, plants, animals, humans; key 
for energy homeostasis
Fructose PTS transporters Transport system targets 
the fructose component of 
substrates, thus allowing use of 
fructose, sucrose, inulin, and 
both FFn and GFn-type FOS.
L. rhamnosus GG contains a fructose 
PTS transporter, which allows 
growth on various types of FOS and 
inulin
Lactose PTS transporters Transport system targets the 
lactose component of substrates
L. gasseri contains a lactose PTS 
transporter [22]
LacS and LacY permeases MFS-type transport systems 
enabling transport of molecules 
with lactose module. The 
LacS transport system allows 
a microbe to use lactose, GOS 
(with lactose terminus), and 
lactitol. LacS and LacY differ 
based upon source family.
LacS is stated to be the sole 
transporter for GOS, with 
specificity for β-galactosides [22].
Sucrose permease Transport of substrates with a 
sucrose module, such as GFn-
type FOS.
CUT = Carbohydrate Uptake Transporter; FFn = FOS comprised of “n” fructose (F) subunits and a fructose terminal 
unit; GFn = FOS containing “n” fructose (F) subunits and a terminal glucose (G); PTS = phosphoenolpyruvate 
phosphotransferase.
Table 2. 
Key Transmembrane transport systems.
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Starch, owing to its high DP and complex branched structure, would be degraded 
in the presence of extracellular enzymes that can act on α-1,4 and α-1,6 linkages 
between glucose subunits. Certain Bifidobacteria, including B. pseudolongum and B. 
breve have the necessary enzymes for extracellular starch utilization [29].
Microbes such as the L. acidophilus cluster (including L. johnsonii, L. helveticus, 
L. reuteri and L. plantarum) contain LacS permease and β-galactosidase which allow 
these microbes to transport GOS into the cell, then break it down into glucose and 
galactose for metabolism [28].
Several Bifidobacteria contain the hydrolytic enzymes needed to break down the 
β-1,4 linkages present in xylooligosaccharides (XOS) and XOS with arabinose side 
groups (AXOS). Key enzymes include β-xylosidase and β-xylanase, the latter which 
breaks down longer chain XOS into shorter chains, ultimately xylobiose, that may 
be converted into xylose using β-xylosidase. AXOS requires arabinofuranosidase 
enzymes to process the arabinose side group. Some carbohydrate esterases may also be 
present to deal with acetyl or feruloyl side groups. The enzymes may be intracellular or 
extracellular; intracellular enzymes also require transporters such as an ABC transport 
system to act on the longer chain oligomers. Ejby et al. [30] noted that ABC transport-
ers specific to XOS are exclusive to Bifidobacteria. B. lactis, B. breve, and B. bifidum are 
among the many species of Bifidobacteria that have the requisite enzymes and trans-
port systems for utilization of short and longer chain XOS and AXOS. Crossfeeding 
of Bifidobacteria is aided by Bacteroides and Prevotella, which act as primary degraders 
that break down insoluble xylan in plant fiber into soluble oligosaccharides.
The wide variation in structures of prebiotics, along with the different transport 
and enzyme systems, ultimately dictate the selectivity of the prebiotic in a mixed 
culture. Monoculture systems provide some useful insights into the utilization of 
prebiotics by various substrates. Makelainen et al. [31] conducted a thorough study 
of the growth of >15 microbes, some beneficial, some pathogenic, in the presence 
of 11 different carbohydrate sources. Aggregate growth over 24 hours was reported 
as the area under the curve of DP600 measurements. Figures 2–6 show growth 
of various probiotics and pathogenic microbes on glucose, FOS, GOS, scXOS, and 
XOS, respectively. As expected, all bacteria grew well on glucose (Figure 2), consis-
tent with the widespread ability of microbes to utilize simple 6-carbon sugars.
Low DP FFn-FOS proved to be a good substrate for several strains of 
Bifidobacteria, along with L. paracasei and L. acidophilus, but was also used by E. 
coli EHEC, S. epidermis, and C. perfringens, among pathogenic bacteria tested. GOS 
also grew well on Bifidobacteria and Lactobacilli, but also proved to be an excellent 
substrate for several pathogenic bacteria, including E. coli and C. perfringens.
Consistent with the unique chemical structure and enzyme/transporter 
requirements, there was less microbial growth on scXOS and XOS. Fewer strains of 
Bifidobacteria utilized XOS, along with select strains of Lactobacillus. Li et al., in a 
study using 29 Lactobacillus strains and 35 strains of Bifidobacterium, observed that 
all Bifidobacterium strains tested grew on a high dose of XOS, and 30 of 35 strains 
grew on low dose XOS [32]. They also noted that Lactobacillus strains were able to uti-
lize XOS, albeit with fewer strains and at lower efficiency compared to Bifidobacteria.
However, importantly, Makelainen et al. [31] noted minimal growth of patho-
genic bacteria in the presence of XOS (Figures 5 and 6), consistent with a much 
higher selectivity of XOS for beneficial bacteria. This is a key advantage in a mixed 
microbial environment such as the GI tract. Bifidobacteria and Lactobacillus species 
have to compete with many more bacteria for FOS and GOS, which thus increases 
the dose required for efficacy. XOS, conversely, is better targeted to Bifidobacteria, 
and in a mixed culture, could be efficacious at a lower dose.
The aggregate area under the curve data reported by Makelainen et al. [31] do 
not, however, capture changes in growth rates, which can vary over time. Similarly, 
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any issues with viability of microbes could be masked by rapid early growth, which 
may not be sustained. Figure 7 illustrates growth of a strain of B. breve on FOS, XOS, 
and inulin, showing temporal effects. A noteworthy observation is that viability 
of B. breve decreased significantly after ~12–16 hours if grown on FOS or inulin, 
whereas growth on XOS sustained B. breve for a longer period, even up to 48 hours. 
Figure 2. 
Microbial growth on glucose (positive control). Data from Makelainen et al. [31].
Figure 3. 
Microbial growth on FFn FOS (DP 2–7). FFn = FOS comprised exclusively of fructose (F) subunits. Data from 
Makelainen et al. [31].
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This may have important implications in terms of sustaining key microbes in the 
digestive tract.
In the next section, we describe health impacts of prebiotics, with a particular 
emphasis on studies with XOS, AXOS, and MOS, due to their distinct chemical 
structures and selectivity for beneficial bacteria.
Figure 5. 
Microbial growth on short chain XOS (scXOS; DP 2–5). Data from Makelainen et al. [31].
Figure 4. 
Microbial growth on GGan GOS (DP 3–5). GGan GOS is comprised of n subunits of galactose (Ga) with a 
terminal glucose (G) subunit. Data from Makelainen et al. [31].
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4. Health impacts of prebiotics
Stimulating the growth of beneficial bacteria with prebiotics can lead to a 
cascade of health effects, as illustrated in Figure 8. Much of the historical focus had 
been on Bifidobacterium spp. and Lactobacillus spp., although more recently, benefi-
cial health outcomes have been associated with other microbial species as well. Short 
chain fatty acids, primarily acetate, propionate, and butyrate, along with lactate, 
are produced by fermentation of non-digestible fibers and prebiotics, potentially 
reducing the pH within the colon. This can promote absorption of minerals such as 
Figure 7. 
Comparative growth of B. breve on FOS, XOS, and inulin.
Figure 6. 
Microbial growth on XOS (DP 2–10). Data from Makelainen et al. [31].
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calcium, and limit growth of yeasts, potentially pathogenic bacteria, and microbes 
responsible for protein fermentation [3]. The extent of such a pH reduction in vivo 
is difficult to establish, however, given that greater than 90% of SCFAs are typically 
absorbed, and as little as 5% may be excreted [33]. Thus, changes in fecal SCFA 
levels (or pH) may be difficult to detect, or may not represent what is present in 
the digestive tract. Autopsy samples indicate SCFA levels are an order of magnitude 
greater in the cecum than the ileum, and that levels decrease from about 70–140 mM 
in the proximal colon to 20–70 mM in the distal colon [33].
The effect of increased colonic SCFA production may, however, be observed in 
the form of distal health impacts mediated by the SCFAs that have been absorbed 
into the bloodstream. Each SCFA has a different effect on host metabolism, yet the 
direct effect of a prebiotic on SCFAs can be difficult to establish, due to crossfeeding 
between microbes that directly consume the prebiotic and other microbes within 
the digestive tract. Dietary fiber intake also affects SCFAs, further clouding inter-
pretation of fecal SCFA levels. The impacts of prebiotics on SCFA levels are easier 
to detect via in vitro cultures, particularly monocultures, and in gut simulators that 
contain mixed microbial communities that enable cross-feeding, such as acetate 
production via one class of microbes, and acetate conversion into butyrate by, e.g., 
E. rectale, F. prausnitzii, or Roseburia spp. [3].
SCFAs provide energy for colonocytes, and, after absorption into the portal vein, 
are metabolized by the liver, modulating cholesterol synthesis, maintaining glucose 
homeostasis in peripheral tissues, and producing long chain fatty acids. SCFAs can 
act on leukocytes that modulate immune responses, beneficially impact hormones 
that influence satiety, and influence neural signals that modulate appetite and 
food intake via the gut-brain axis [3]. Acetate can influence hormones responsible 
Figure 8. 
Health impacts associated with prebiotic intake.
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for cholesterol production, and may be transported to the muscle and the brain; 
acetate may thus contribute to effects attributed to the “Gut-Brain Axis”. Propionate 
can play a role in hepatic regulation of glucose and synthesis of cholesterol, while 
butyrate can promote growth of protective colonocytes via colonic epithelial cells. 
Consequently, microbes fed directly or indirectly by prebiotics can influence health 
via SCFAs that act either locally within the digestive tract, or distally, mainly via the 
liver, and to a lesser extent, in the muscle, kidney, heart, and brain [3].
4.1 XOS/AXOS
As noted previously, XOS and AXOS are oligomers of 5-carbon sugars, con-
nected by β-1,4 bonds. Fewer types of microbes contain the enzymes and transport 
systems necessary to utilize XOS and AXOS, thus conferring greater selectivity to 
beneficial bacteria (see Figures 5 and 6). Mannooligosaccharides (MOS), although 
based upon a 6-carbon sugar backbone, are connected via β-1,4 bonds that also 
render them less susceptible to microbial utilization. In this section, we summarize 
clinical trial results from these novel prebiotic oligosaccharides.
Tables 3 and 4 summarize clinical trial results with XOS and AXOS, respectively, 
outlining impacts on the microbiome and various clinical biomarkers. Clinical trials 
with XOS were conducted with doses ranging from 0.4 to 8 g per day; most were in 
the range from 1 to 3 g per day. A statistically significant increase in Bifidobacteria 
was observed in most trials with XOS [34–39]. Improvements in laxation were noted 
by Childs et al. [34], Chung et al. [35], Iino et al. [40], and Tateyama et al. [41]; 
the latter was a study in constipated pregnant women. Studies by Childs et al. [34], 
Na and Kim [39], and Sheu et al. [42] observed improvements in triglyceride and 
cholesterol levels, at doses as low as 2.8 g/d, whereas Yang et al. [43] did not observe 
changes in triglycerides when dosing XOS at 2 g/d (2.8 g/d of a 70% purity product). 
Yang et al. [43] observed a tendency towards a reduction in OGTT insulin in predia-
betes patients dosed with 2.8 g/d of 70% XOS, but no effect on blood glucose, unlike 
Na and Kim [39], who noted a reduction in blood glucose at a XOS dose of 2.8 g/day. 
Sheu et al. [42], in a trial with diabetic patients receiving 4 g/d of XOS, observed a 
statistically significant reduction in blood glucose and HbA1C.
Studies with AXOS complement studies with XOS, since most AXOS products 
are comprised of at least ~50% XOS. All studies noted an increase in Bifidobacteria 
[44–48]. Francois et al. [45] and Walton et al. [48] observed increased fecal levels 
of SCFAs (acetate, propionate, and butyrate). Reductions in cresol, indicative of 
reduced protein fermentation, were observed by Cloetens et al. [44] and Francois 
et al. [45] with AXOS, and Lecerf et al. [38] with XOS.
The bifidogenic effect and health benefits observed in the various clinical trials 
with XOS and AXOS where generally observed at a dose less than 4 g/d. By com-
parison, approximately 10–20 g/d of FOS is needed to trigger a bifidogenic effect, 
and the required inulin dose is stated to be at least 15 g/d [49, 50]. Alfa et al. [51] 
required a dose of 30 g/d of resistant starch to enhance Bifidobacterium levels.
Miremadi et al. [52] summarized clinical trials in which various prebiotics were 
evaluated to assess cardiovascular impacts, particularly reductions in cholesterol, 
lipids and blood pressure. No improvements to lipid profile were observed with 
5.5 g of GOS or 20 g/d of FOS (type not specified), whereas triglyceride levels 
improved following consumption of 10 and 20 g/d of inulin. Similarly, Alles et al. 
were unable to detect changes in blood glucose and lipid profiles following adminis-
tration of 15 g/d FOS [53].
The higher doses required for a bifidogenic effect or clinical efficacy compared 
to XOS and AXOS is likely due to the greater selectivity of XOS and AXOS for 
beneficial bacteria, versus the widespread utilization of FOS and GOS [11, 23, 31]. 
Prebiotics and Probiotics - Potential Benefits in Nutrition and Health
14
For example, Mao et al. [23] found that 237 out of 453 strains (114 genera) of gut 
bacteria contained the necessary transporters and enzymes for some type/degree of 
FOS utilization, suggesting fairly widespread utilization of FOS, which will impact 
the effective dose required to grow the targeted beneficial bacteria. Similarly, Goh 
et al. [11] note the widespread ability of microbes to utilize lactose, suggesting the 
presence of LacS (or similar) transporters and enzymes in many microbes that 
Table 3. 
Summary of clinical trials with XOS.
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would allow use of the GGan type of GOS. This is consistent with the observations 
of Makelainen et al. [31], who also observed excellent growth of many species, ben-
eficial and pathogenic, on GOS (see also Figure 4). Ultimately, increased sharing 
of prebiotic substrates among bacteria means that a higher dose is needed to trigger 
sufficient growth of the targeted beneficial bacteria that produce the desired health 
benefits.
4.2 MOS
Manno-oligosaccharides (MOS), extracted from yeast cell walls, coffee or 
biomass rich in mannan, are typically comprised of up to 6 mannose subunits con-
nected by β-1,4 bonds. MOS have not been as extensively evaluated in humans, but 
have been recognized as a nutritional supplement for livestock.
Salinardi et al. [54] observed a reduction in body volume and adipose tissue in 
men consuming 4 g/d MOS, attributed to an increase in fat excretion in the feces 
or inhibition of hepatic lipogenesis. Kumao et al. [55] observed a reduction in fat 
utilization and an increase in fecal fat excretion in people consuming 3 g/d of MOS 
for 7 days. St.-Onge et al. [56] also observed a reduction in body weight and adipose 
tissue following consumption of 4 g/d MOS for 12 weeks. Umemura et al. evaluated 
Table 4. 
Summary of clinical trials with AXOS.
Prebiotics and Probiotics - Potential Benefits in Nutrition and Health
16
the impact of 1 g/d of MOS consumption on fecal microbiota and laxation [57]. 
They noted an increased ratio of Bifidobacterium spp., and enhanced defecation 
frequency/volume, reducing constipation. A study in mice by Zheng et al. [58] sug-
gested that MOS acted synergistically with metformin, altering the gut microbiota 
in a manner that would decrease clinical diabetic parameters, including a reduction 
in blood glucose. This may have promise for future clinical trials and application of 
MOS plus metformin for management of type II diabetes.
Jahromi et al. [59] examined MOS supplementation (1 g/kg) to broiler chicks, 
and observed increased levels of Lactobacillus spp. and Bifidobacteria spp., while 
reducing levels of E. coli and Enterobacter by >50%. Navidshad et al. [60] compared 
MOS derived from yeast cell walls with MOS from palm kernel expeller, assessing 
their efficacy as a supplement (2 g/kg) to the diet of broiler chicks. The yeast-
derived MOS improved weight gain, while reducing the intestinal percentage of 
E. coli in the birds. MOS has been reported to have receptors for fimbriae on E. 
coli, which can help to control or limit colonization within the digestive tract [61]. 
Jahromi et al. [62] also evaluated In Ovo injection of MOS, and feeding of MOS 
to chicks. The single In Ovo injection had some short term but limited long term 
effects, other than an increase in Bifidobacterium spp. at 14 days. Feeding MOS in 
the diet markedly improved levels of Lactobacillus and Bifidobacteria, while reduc-
ing levels of pathogenic strains of Salmonella, E. coli, and Campylobacter. Adding 
MOS to the diet also improved levels of serum immunoglobulins IgA, IgM, and 
IgG. The immunomodulatory effect of MOS in chicks was stated to be a significant 
benefit that could help improve productivity, and reduce disease (thereby reducing 
use of antibiotics). Zhao et al. [63] studied the impact of supplementing 0.1 wt% 
MOS or 0.1 wt% FOS in weanling pigs over 28 days. They observed greater average 
daily weight gain and average daily feed intake in pigs consuming MOS compared 
to controls. Nutrient digestibility also improved, along with diarrhea score (poten-
tially by inhibiting E. coli). Collectively, the authors concluded that MOS could 
enhance piglet growth and health.
5. Summary
Increased understanding of enzyme and transporter expression in various 
microbes, and key differences between the various classes of enzymes and types of 
transporters, are enhancing our knowledge about microbial selectivity for sub-
strates, including prebiotics. Differences in chemical structure, degree of polym-
erization, and bonds between subunits affect microbial utilization of prebiotics. 
Novel prebiotics derived from xylan, arabinan, and mannan are comprised of less 
common subunits based on 5 carbon sugars (xylose, arabinose), and/or are con-
nected via β-bonds. The unique types of subunits and bond structures confer greater 
selectivity for beneficial bacteria, and health benefits at a lower dose compared to 
conventional prebiotics comprised of glucose, fructose and galactose subunits.
Clinical trials with XOS and AXOS led to improvements in laxation, triglyc-
erides, cholesterol, and blood glucose, typically at doses from 1 to 3 g per day, 
far less than the 10–30 g per day required with FOS, GOS, inulin, and resistant 
starch. Preliminary clinical trials with MOS suggested the potential for weight 
management and reductions in adipose tissue at doses in the range of 4 g per day. 
Furthermore, MOS seems to have a unique capacity to inhibit proliferation of E. 
coli, and its addition to livestock feed has improved livestock health with a concur-
rent reduction in antibiotic use. Ultimately, these novel prebiotics may usher in a 
new era of prebiotic utilization, driven by their greater selectivity for beneficial 
bacteria, and easier product formulation and efficacy at a lower dose.
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